News

As part of the agreement, BrainLAB will supply and install its iPlan Flow software at all clinical sites participating in the pre-pivotal trial. The software will incorporate patient-specific

Dalton Medicinal Chemistry will utilize their proprietary insights to design and synthesize several novel classes of compounds against selected riboswitch targets. BioRelix will advance these compounds using their

The new Juvenile Diabetes Research Foundation (JDRF)-Lilly project will support research on biomarkers for pancreatic beta cell mass and function. The JDRF-Lilly Innovative and Academic Research and Development

R84 is a selective, fully human monoclonal antibody that blocks the cancer-promoting agent vascular endothelial growth factor. The study results showed that tumor-associated macrophages are reduced after R84

The Entelos cardiovascular PhysioLab platform is a predictive computer model that simulates patients and drug effects, and represents key biological mechanisms and disease processes that can help to

Results of company’s ocular discovery program suggest that sonepcizumab may be a valuable therapeutic in the treatment of diabetic retinopathy, dry age-related macular degeneration(AMD), uveitis, and scar formation

Zyrtec-D, an over-the-counter version of Zyrtec, has been approved for the relief of symptoms due to hay fever or other upper respiratory allergies such as runny nose, sneezing,

First, Nastech plans to concentrate its resources on its Phase II clinical development programs that are currently ongoing or planned including PYY3-36 nasal spray for obesity, insulin nasal

Under the terms of the merger agreement, Tutogen shareholders will receive 1.22 shares of newly issued RTI common stock in exchange for each share of Tutogen common stock